Publication | Closed Access

Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial

VaccinationVaccine SafetyVaccine DevelopmentDose-escalation Phase 1/2Vaccine ResearchImmunologyInfection ControlMedicineLyme BorreliosisParasitologyTick-borne DiseaseHealthy Adults